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Background: The OPTION trial results showed that premenopausal women with early stage breast cancer
(EBC) receiving chemotherapy benefited from ovarian function protection with goserelin. The impact of
treatments on patient reported Quality of Life (QoL) were also examined.
Patients and methods: 227 pre-menopausal women with EBC, were randomly assigned to chemo-
therapy±goserelin (C±G); 132 (58%) were ER-ve. Patients were stratified by age (40 years and >40
years). QoL was assessed with the Functional Assessment of Cancer Therapy e Breast, and Endocrine
Symptom checklist at baseline (pre-treatment), 3, 6, 12, 18 and 24 months, then annually to 5 years.
Treatment Outcome Index (TOI) score was the primary outcome.
Results: 213 patients were available for QoL analysis. There was a significant decrease in TOI scores for
both treatment groups at 3 and 6 months that returned to pre-treatment levels at 12 months, then
continued to increase reflecting improved QoL. By 3 months there was a significant difference from
baseline in both groups for menopausal symptoms, and between groups in the proportion experiencing
hot flushes at any time. The C þ G group experienced higher levels of vasomotor symptoms generally
during the treatment phase; by 24 months, the short-term negative effect of goserelin was reversed, with
hot flushes twice as frequent in the chemotherapy only group (40.9% vs 21.3%).
Conclusions: These results show that young women diagnosed with breast cancer experienced only a
short-term decrease in QoL from the addition of goserelin, in order to preserve ovarian function during
chemotherapy treatment.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The improved survival of women with early breast cancer (EBC)
has led to an increased interest in the long-term consequences of
treatment. Chemotherapy treatment-related side effects concern
women regardless of age, e.g. fatigue, hair loss, but it is the impact
of ovarian damage from chemotherapy that is a specific issue for
the premenopausal patient [1]. The harm from treatments range
from follicular damage with preserved menses to temporary ame-
norrhoea, irregular menses, and early menopause (premature
ovarian insufficiency, POI) resulting in a loss of fertility. Recall of
menses may be an unreliable indicator of POI unless based on ar Ltd. This is an open access articledaily diary, and while amenorrhoea is clear, infrequent, or irregular
menses may indicate incipient POI [2].
These young women with breast cancer face unique challenges.
Efforts to protect fertility include freezing embryos (IVF), eggs or
ovarian tissue before starting treatment, and the use ovarian sup-
pression [3]. In these circumstances, some womenwill have a plan,
while others may find it harder to decide and prefer to start
chemotherapy and wait to see if fertility returns when treatment is
over [4]. A European prospective study (Helping Ourselves, Helping
Others) revealed that 64% of young breast cancer patients were
very concerned about becoming infertile after chemotherapy [1]. In
others, 68% reported sexual dysfunction, and 58% concerns over
fertility two years post diagnosis, and sexual problems [5,6].
One strategy to reduce the risk of treatment induced premature
menopause includes suppressing the ovaries temporarily with a
gonadotropin-releasing hormone agonist (GnRHa), but data fromunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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included a limited number of patients and reported results of their
primary endpoint (i.e. chemotherapy-induced POI) rather than
successful post treatment pregnancies. A review of 873 patients
from five trials noted that overall POI rate was 14.1% in the GnRHa
group and 30.9% in the control group (adjusted odds ratio, 0.38;
95% CI, 0.26 to 0.57; P < 0.001) [7]. A total of 37 (10.3%) patients had
at least one post-treatment pregnancy in the GnRHa group and 20
(5.5%) in the control group. Importantly no significant differences in
disease-free survival and overall survival were observed between
the groups. These data provided evidence for the safety of tempo-
rary ovarian suppression with GnRHa during chemotherapy as an
available option to reduce the likelihood of chemotherapy-induced
POI, and potentially improve future fertility in premenopausal pa-
tients with EBC.
The OPTION trial was set up to establish specifically if the use of
goserelin in women who require chemotherapy for operable hor-
mone-insensitive breast cancer or for whom ovarian suppression is
not considered a necessary part of treatment, may reduce the risk
of POI [8]. The primary outcome was the prevalence of amenor-
rhoea at 12e24 months, secondarily combined with elevated
follicle-stimulation hormone (FSH) concentration giving the prev-
alence of POI. The original protocol restricted the entry of patients
to those with ER negative tumours only, but patients with ER
positive tumours for whom the investigator did not deem ovarian
suppression necessary as part of the treatment, were allowed entry
to the trial after a protocol amendment.
A total of 227 patients were randomised, and the primary
analysis was conducted on 202 patients. Goserelin reduced the
prevalence of amenorrhoea between 12 and 24months to 22%
versus 38% in the control group (P ¼ 0.015) and the prevalence of
POI to 18.5% versus 34.8% in the control group (P ¼ 0.048). Follicle
stimulating hormone concentrations were also lower in all women
treated with goserelin at both 12 and 24months (P ¼ 0.027,
P ¼ 0.001, respectively). Assessment of the ovarian reserve using
anti-Müllerian hormone showed a marked fall in both groups
during treatment to median values of 5% of pre-treatment levels in
the control group, and 7% in the goserelin group, which were not
significantly different between groups. Results showed both out-
comes were significantly reduced in patients receiving goserelin,
but only in younger patients, aged up to 40 years at randomisation
[2]. Despite these benefits, POI has potential adverse consequences,
including decreased quality of life [9], sexual dysfunction [5,6], and
menopausal symptom distress [10] and in the longer term women
are at increased risk of developing osteoporosis, and cardiovascular
disease [11,12].
The impact from POI can be so great that both ESMO [10,13],
ASCO [14] issued international guidelines, advising that risk and
approaches to reduce the associated side effects are discussed as
early as possible with all young women considering chemotherapy
treatments. Given the potential side effects associatedwith POI, it is
surprising that patient reported outcomes (PROs) were rarely
incorporated into the earlier trials. OPTION was one of the few that
collected Quality of Life (QoL) PRO data on the immediate and late
effects of chemotherapy±goserelin treatments. These data are
presented here to help inform patients and health care pro-
fessionals when discussing fertility preservation options.
2. Methods
2.1. Participants
Premenopausal patients with histologically confirmed EBC who
were to receive adjuvant or neo-adjuvant chemotherapy were
eligible for OPTION. Metastatic disease was an exclusion criterion.Patients who had had prior chemo or endocrine therapy were
ineligible. Participants were randomised to receive a 3.6-mg
goserelin implant or nothing, starting at least 1week but prefer-
ably 2weeks before chemotherapy. Goserelin treatment continued
3e4 weekly until the end of the chemotherapy, which had to start
within 8weeks of definitive surgery. Radiotherapy was as per
standard protocol for each centre. Participants kept a menstruation
diary for 24months from the start of chemotherapy. The detailed
description of the trial design was published in 2017 [2].
2.2. Quality of life measures
Patients recruited to the OPTION trial completed the Functional
Assessment of Cancer Therapy FACT-B [15], a standardised breast
cancer quality of life measure, together with the Endocrine Sub-
scale (FACT-ES) [16].
The FACTeB is a 36-item questionnaire that measures both
general QoL associated with cancer (27 questions, referred to as the
FACT-General [FACTeG]), and additional concerns more specific to
women with breast cancer (nine items, referred to as the breast
cancer subscale). The ES was designed for use with the FACTeB and
comprises 19 items.
The FACT ES has 4 subscales, Physical Well Being (PWB) 7 items,
Social Well Being (SWB) 7 items, Emotional Well Being (EWB) 6
items, Functional Well Being (FWB) 7 items and a 19-item ES.
Participants indicated, using a five-point Likert scale ranging from
0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), to 4 (very
much), to what degree each item has applied over the last 7 days.
High scores equate with a good QoL and lower scores equate with a
poorer QoL. The tools sit within the Functional Assessment of
Chronic Illness Therapy (FACIT) measurement system [17].
Baseline questionnaires were completed by patients without
assistance prior to randomisation with follow-up assessments at 3,
6, 12, 18, 24 months after therapy started; and then yearly there-
after until 5 years (i.e. 36, 48, 60 months).
2.3. Statistical methods
The primary endpoint was the Treatment Outcome Index (TOI)
score: this comprised the 23 items of the Physical and Functional
well-being and Breast Cancer Subscale. Secondary endpoints were-
1) FACT-ES score: total of all 36 þ 19 ¼ 55 items
2) ES score: total of 19 Endocrine symptom scores
3) Individual endocrine symptom scores
For TOI, ES and FACT-ES scores, change from baseline to each
time point was calculated for all patients with valid baseline and
follow-up questionnaires; no imputation was made for missing
data.
Mixed model repeated measures analyses were performed
where the dependent variable was the change from baseline, the
fixed factors were time point, treatment and the interaction of time
with treatment, and the baseline value of the endpoint was
included as a covariate in the model. A random effect was included
for patients. The model assumed a first order autoregressive cor-
relation structure. The estimate of the treatment term provides an
overall measure of treatment difference for the whole period of
3e60 months. Where the interaction term is significant, there is
evidence that the treatment difference varies across time points.
Where neither the treatment term nor the interaction term is sig-
nificant, there is no evidence of a treatment effect at any time point.
At each time point, 95% confidence intervals for the change from
baseline, based on the repeated measures model, were calculated
for each treatment group.
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clinical categories: A) Vasomotor symptoms, B) Neuropsychological
symptoms, C) Gastro-intestinal (GI) symptoms and D) Gynaecologic
symptoms. ‘Joint Pains’ was presented separately. For each indi-
vidual symptom score at each time point, a binary variable was
created indicating ‘Clinically significant effect’, defined as a
response of ‘Very much’ or ‘Quite a bit’. These data were summar-
ised as numbers and percentages for each symptom and each time
point, plus an exact 95% confidence interval for the percentage
(calculated using the Clopper Pearson method).
In addition, a binary variable for each symptom score was
created indicating whether or not a patient reported a clinically
significant effect at any time; the odds ratios (OR) for this binary
variable was calculated for each symptom plus an exact 95% con-
fidence interval for the percentage as above. ORs less than 1 imply a
better QoL for the treatment including goserelin: i.e. the odds of
experiencing the symptom were lower in the group treated with
goserelin. Forest plots showing this OR, with a 95% confidence in-
terval (CI) were created.
The analysis was conducted using R [18].
3. Results
Two hundred and twenty-seven patients were randomised be-
tween August 26, 2004 and December 23, 2009. The age distribu-
tion, ER status, definitive surgery, planned chemotherapy cycles
and hormone levels for the 227 patients randomised are described
in Table 1, and did not differ between the two groups, of these 213
completed at least one QoL questionnaire. Table 2 shows the
number of QoL questionnaires completed at each follow up timeTable 1
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3.1. TOI results
Table A1 (Appendix A) provides summary statistics for the TOI at
each time point. Table A2 provides the observedmean change from
baseline and the least squares means and 95% confidence intervals
for the change from baseline in TOI at each time point calculated
from the repeated measures model.
Fig. 1 illustrates the change from baseline for TOI for each
treatment group. In the mixed model analysis, time point was a
significant factor in the model (P < 0.001), but neither treatment
group (P ¼ 0.56) nor the interaction of treatment with time
(P ¼ 0.60) was significant.
There was no evidence of any difference between the treatment
groups. For both treatment groups, therewere significant decreases
in the TOI at both 3 months and 6 months, corresponding to the
period of chemotherapy treatment. TOI returned to pre-treatment
levels at 12 months, then continued to increase, with higher esti-
mated scores than pre-treatment from 12 months onwards (C þ G)
and respectively from 18 months onwards (C only). For patients
treated with C only the increase in estimated scores was significant
from 24 months onwards, while for patients treated with C þ G the
increase was significant at 36 months and at 60 months. (This
should not be interpreted as a difference between the treatment
arms; data are limited in the later part of the study.)
3.2. ES results
Fig. 2a and Tables B1 and B2 (Appendix A) show the summaryChemotherapy plus goserelin Chemotherapy
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0.9, 46.1 1, 222
e of such values is 6 (Oestradiol, before chemo), 33 (Oestradiol after chemo), 0 (FSH,
Table 2
Quality of Life Questionnaires completed at each time point.
Randomised Responses at each time point (months)
0 3 6 12 18 24 36 48 60
All N 227 203 193 186 178 169 163 114 83 40
%a 89% 85% 82% 78% 74% 72% 50% 37% 18%
Chemotherapy N 106 96 91 84 83 79 75 57 41 22
plus goserelin % 91% 86% 79% 78% 75% 71% 54% 39% 21%
Chemotherapy N 121 107 102 102 95 90 88 57 42 18
% 88% 84% 84% 79% 74% 73% 47% 35% 15%
a Percentage of randomised.
Fig. 1. Estimated Mean TOI change from baseline with 95% CIs (from repeated measures model).
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confidence intervals for the changes from baseline at each time
point. In the mixed model analysis, time point was a significant
factor in themodel (P < 0.001). Treatment groupwas not significant
overall (P ¼ 0.74) but the interaction of treatment with time was
marginally significant (P ¼ 0.02) suggesting that the treatment ef-
fect may be time dependent. The figure suggests an earlier wors-
ening of symptoms in the goserelin group. The pattern was similar
to that seen for the TOI, with a reduction from baseline at 3 and 6
months followed by an upward trend; however at 60 months the
values had not returned to pre-treatment levels although the data
from this time point are limited.3.3. FACT-ES total score results
The FACT-ES total scores were again similar between the treat-
ment groups for each of the time points (Fig. 2b; Tables C1, C2,
Appendix A). In the mixed model analysis, time point was a sig-
nificant factor in the model (P < 0.001), but neither treatment
group (P ¼ 0.81) nor the interaction of treatment with time
(P ¼ 0.74) was significant. By 60 months the values had returned topre-treatment levels.3.4. FACT-ES symptoms
Fig. 3 shows the forest plots for the odds ratios comparing the
treatment groups for the proportions of patients reporting each
symptom at a clinically significant level (i.e. ‘very much’ or ‘quite a
bit’) at any time. ORs less than 1 imply a better QoL for the treat-
ment including goserelin: i.e. the odds of experiencing the symp-
tom being lower in the group treated with goserelin. Considerable
proportions of patients in each treatment group reported that at
some point, hot flushes, cold and night sweats or joint pains had
affected them quite a bit or very much. A larger proportion of pa-
tients in the C þ G group experienced clinically significant vaso-
motor symptoms compared to those receiving C only. There was a
statistically significant difference between groups in proportions
experiencing significant hot flushes (76.5% C þ G group, 61.7% C
group: odds ratio 2.02 (95% confidence interval (1.11, 3.68)).
Fig. 3 also shows that there were no statistically significant
differences between groups in proportions of patients reporting
each neuropsychological symptom or in reporting each GI
Fig. 2. a: Estimated Mean Endocrine Symptom (ES) change from baseline with 95% CIs (from repeated measures model) b: Estimated Mean FACT-ES change from baseline with 95%
CIs (from repeated measures model).
L. R et al. / The Breast 52 (2020) 122e131126symptom at any time. Proportions experiencing clinically signifi-
cant symptoms were marginally higher in the C only group except
for weight gain, where a slightly higher proportion of patients inthe C þ G group experienced clinically significant symptoms. There
was a statistically significant difference between groups for loss of
interest in sex with 66.3% in the Cþ G group and 51.8% in the C only
Fig. 3. Odds ratios (ORs) with 95% CIs and proportions of patients reporting clinically significant symptoms at any time.
L. R et al. / The Breast 52 (2020) 122e131 127group reporting this at any time point (odds ratio 1.84 (95% confi-
dence interval (1.05, 3.21)).
Fig. 4 shows the proportions of patients reporting clinically
significant vasomotor symptoms at each time point (hot flushes;
cold sweats and night sweats). At 24 months, when the main effect
of goserelinwas observed in respect of menses returning, the short-
term (3e6 months) negative effect of goserelin was reversed with
hot flushes being twice as frequent in the C only group (40.9% (95%
confidence interval (30.5%, 51.9%) vs 21.3% (95% confidence interval
(12.7%, 32.3%)).4. Discussion
The OPTION sub study examined QoL in women receiving
chemotherapy with or without a reversible suppressor of ovarian
function (goserelin). During treatment there was an increase in
some endocrine symptoms in both groups and an associated
deterioration in overall QoL by three months, which gradually
started to improve after six months but did not return to pre-
treatment levels for most women.
There was evidence of a difference between the groups during
the treatment phase, with a larger incidence of vasomotor symp-
toms in the goserelin group. The drug had an immediate impact on
vasomotor endocrine symptoms as compared to the
chemotherapy-only group where these symptoms are likelier to
evolve more slowly, and possibly incompletely, as not every patient
who has chemotherapy experiences a permanent menopause.
However, by 24 months the pattern had reversed and higher pro-
portions of women who had received chemotherapy-only were
reporting bothersome endocrine symptoms. The finding wasconsistent with the clinical trial analysis where 38.3% of the
chemotherapy-only group became menopausal due to the
chemotherapy; proportions differed according to age group (those
over 40 years 54.2%; those 40 years and under 25.4%) [2].
It is difficult to compare the OPTION QoL results directly with
other breast cancer ovarian suppression trials as some did not
include patient reported outcomes (PROs), for example POEMS
S0230 (Prevention of Early Menopause Study) [19]. Others e.g. SOFT
(Suppression of Ovarian Function) and its sister trial TEXT (Trip-
torelin with either EXemestane or Tamoxifen) involved pre-
menopausal women with hormone sensitive breast cancer not all
of whom received chemotherapy. These trials used the Interna-
tional Breast Cancer Study Group (IBCSG) QoL core form to collect
PRO data at baseline, every 6 months for 2 years and then every
year in years 3e6. PRO analysis involved changes from baseline on
the global and symptom indicators, across time. Results showed
that ovarian function suppression (OFS) with tamoxifen or
exemestane impacted on QoL with distinct effects of the two
treatments on endocrine symptoms [20]. Subsequently analysis of a
subset of patients showed that treatment induced symptoms pre-
dicted sexual problems during the first 2 years [6].
Another study, MENOCOR, examines the impact of chemo-
therapy induced menopause (CIM) on QoL [9]. Preliminary results
from 58 women (age, 18e46 years) show that overall QoL, perhaps
not surprisingly, differed significantly for both CIM (n ¼ 41) and
non-CIM (n ¼ 17) groups at six months post chemotherapy.
Menopausal symptoms however were greater in the CIM group
who were significantly older. In OPTION the rate of menopause
overall for women in the goserelin group was 22.1%; 42.9% in those
>40 years and 10%  40years. In the QoL analysis we did not
Fig. 4. Proportions reporting clinically significant vasomotor symptoms (95% CIs:
Clopper Pearson).
L. R et al. / The Breast 52 (2020) 122e131128attempt to look at the age sub-groups separately but it would be
reasonable to assume that for the younger women, short term
decline in QoL from goserelin is counterbalanced by a longer term
gain in association with preserved ovarian function.
Limitations of our study include themodest size of the40years
age group, where the largest effects of ovarian protection were al-
ways likeliest to be strongest but results still give an insight into the
affect ovarian suppression has on QoL. In addition, subgroup
analysis for the differing effect of endocrine treatment on QoL
(tamoxifen for premenopausal, aromatase inhibitors for post-
menopausal) would have been futile as over the 5 years, more
women became postmenopausal and others possibly switched
treatments. There is always a challenge collecting longitudinal QoL
clinical trial data, with missing data and a drop in return rates over
time. This was true for the OPTION QoL sub study, and we have no
information on the reasons why, but missing data were balanced
between groups, allowing us confidence in our comparison results.
Finally, a 1980’s study on Hodgkin’s lymphoma in young women
treated by MVPP (mustine, vinblastine, procarbazine, and pred-
nisolone) chemotherapy may be instructive. Most of these signifi-
cantly younger patients recovered menstruation in their 20’s only
to develop menopause in their mid 30’s, many years prematurely
[21]. A similar pattern of delayed ovarian failure in breast cancer
patients would justify protracted follow-up to manage the bone
health and other sequelae of premature menopause.
Our data suggest that women experience a short-term decrease
in QoL from the addition of goserelin to chemotherapy in order to
preserve ovarian function. These findings should give hope to the
many young women with breast cancer who worry about the
negative impact of treatments on fertility. Results should also help
Health Care Professionals to adequately inform young women at
the time of diagnosis about the risk of infertility and the different
available methods for fertility preservation, including the use of
goserelin.Funded
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Trial Outcome Index observed score
Chemotherapy plus Goserelin Chemotherapy
N Mean SE3 Median Min Max N Mean SE Median Min Max
Baseline 95 65.01 1.22 67.00 24.00 89.88 107 65.36 1.27 66.00 25.00 89.00
3 months 91 55.58 1.67 55.00 15.00 91.00 102 53.51 1.57 53.50 22.00 86.00
6 months 84 57.10 1.83 56.50 19.00 92.00 102 55.26 1.70 55.50 15.00 90.00
12 months 83 66.42 1.63 67.00 30.00 91.00 95 65.60 1.56 69.00 28.00 90.00
18 months 79 67.94 1.60 70.00 23.00 89.00 90 68.69 1.66 72.50 17.67 90.00
24 months 75 68.66 1.83 73.00 28.00 92.00 87 68.86 1.71 72.00 19.00 91.00
36 months 57 70.78 2.39 78.00 20.00 92.00 57 70.68 1.88 74.00 27.00 90.00
48 months 41 69.48 2.67 75.00 27.75 90.00 42 70.83 2.51 76.94 29.00 91.00
60 months 22 74.56 3.23 82.00 44.25 92.00 18 75.06 4.06 80.00 30.00 90.00
3 SE e standard error of the mean.Table A2
Trial Outcome Index change from baseline
Chemotherapy plus Goserelin Chemotherapy
Observed Estimated Observed Estimated
N Mean Mean 95% LCL4 95% UCL5 N Mean Mean 95% LCL 95% UCL
3 months 90 9.31 8.99 11.84 6.14 98 11.82 11.93 14.64 9.23
6 months 83 7.91 8.27 11.17 5.37 96 9.66 10.05 12.76 7.34
12 months 82 2.11 1.64 1.28 4.55 89 0.49 0.24 3.01 2.53
18 months 78 2.66 1.71 1.26 4.67 85 3.55 2.41 0.41 5.23
24 months 74 3.41 2.94 0.07 5.95 82 4.35 3.05 0.20 5.91
36 months 55 4.75 3.56 0.30 6.81 53 6.16 4.44 1.22 7.67
48 months 40 3.58 2.11 1.55 5.77 40 6.88 3.81 0.18 7.43
60 months 21 11.27 4.94 0.25 9.64 18 8.00 5.78 0.85 10.71
4 LCL ¼ lower confidence limit.
5 UCL ¼ upper confidence limit.Table B1
Endocrine Symptoms observed score
Chemotherapy plus Goserelin Chemotherapy
N Mean SE Median Min Max N Mean SE Median Min Max
Baseline 95 67.26 0.80 69.00 40.00 76.00 104 67.47 0.76 69.00 33.00 76.00
3 months 91 53.54 1.20 55.88 28.00 74.00 100 57.59 1.11 59.50 19.00 76.00
6 months 84 52.67 1.30 55.00 24.00 74.00 101 53.65 1.31 56.00 18.00 76.00
12 months 83 57.39 1.24 60.00 20.00 76.00 94 57.32 1.23 60.00 24.00 76.00
18 months 79 58.92 1.40 62.00 14.00 76.00 90 58.72 1.33 62.00 24.00 76.00
24 months 75 58.20 1.39 59.00 26.00 76.00 88 56.62 1.39 58.53 22.00 75.00
36 months 57 59.45 1.65 61.00 27.00 76.00 57 57.96 1.79 61.00 22.00 76.00
48 months 41 58.57 2.11 62.00 20.00 75.00 42 59.61 2.01 62.64 31.00 76.00
60 months 22 60.76 2.89 64.50 27.31 76.00 18 60.67 2.71 63.00 30.00 75.00
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FACT-ES Total score observed score
Chemotherapy plus Goserelin Chemotherapy
N Mean SE Median Min Max N Mean SE Median Min Max
Baseline 95 173.76 2.31 180.00 93.00 211.76 104 173.72 2.37 177.00 89.83 213.00
3 months 91 148.91 3.29 150.72 77.00 216.00 100 150.14 3.14 149.50 86.00 211.00
6 months 84 148.21 3.62 151.50 66.00 215.00 101 147.52 3.50 149.00 68.00 217.00
12 months 83 163.52 3.37 158.00 80.00 215.00 94 163.05 3.19 168.50 87.00 213.00
18 months 78 166.59 3.48 170.75 80.17 216.00 89 167.29 3.58 177.00 62.06 212.00
24 months 74 167.63 3.65 174.00 101.00 215.00 87 164.52 3.74 169.00 54.00 216.00
36 months 56 171.46 4.71 185.00 80.77 216.00 57 168.48 4.46 177.00 66.00 215.00
48 months 40 168.39 5.66 177.50 75.08 215.00 42 171.66 5.55 182.06 73.00 219.00
60 months 21 180.12 7.48 190.00 99.56 218.00 18 175.86 8.32 185.83 76.00 207.00
Table C2
FACT-ES Total score change from baseline
Chemotherapy plus Goserelin Chemotherapy
Observed Estimated Observed Estimated
N Mean Mean 95% lcl 95% ucl N Mean Mean 95% lcl 95% ucl
3 months 90 24.55 24.06 29.65 18.47 94 24.27 24.31 29.70 18.91
6 months 83 25.20 26.27 31.95 20.59 92 25.77 26.31 31.72 20.89
12 months 82 8.67 9.66 15.37 3.95 85 11.15 12.74 18.25 7.23
18 months 77 7.73 9.11 14.92 3.30 81 6.62 8.91 14.51 3.31
24 months 73 6.27 7.07 12.97 1.17 80 8.62 10.27 15.91 4.63
36 months 54 4.60 6.69 13.02 0.36 51 3.44 7.60 13.93 1.27
48 months 39 5.99 9.33 16.37 2.30 38 0.38 6.49 13.54 0.57
60 months 20 7.72 2.61 11.56 6.35 17 2.32 3.64 13.13 5.85
Table B2
Endocrine Symptoms change from baseline
Chemotherapy plus Goserelin Chemotherapy
Observed Estimated Observed Estimated
N Mean Mean 95% lcl 95% ucl N Mean Mean 95% lcl 95% ucl
3 months 90 13.56 13.39 15.67 11.12 94 9.89 9.87 12.06 7.67
6 months 83 14.39 14.90 17.22 12.58 92 13.27 13.38 15.59 11.18
12 months 82 9.27 9.54 11.87 7.21 85 10.39 10.80 13.05 8.55
18 months 78 8.29 8.60 10.96 6.24 82 8.75 9.78 12.06 7.50
24 months 74 8.74 9.25 11.65 6.86 80 11.14 11.43 13.73 9.13
36 months 55 7.84 8.91 11.50 6.33 51 8.56 10.23 12.82 7.64
48 months 40 8.69 10.08 12.96 7.21 38 7.89 9.56 12.44 6.67
60 months 21 5.31 8.43 12.06 4.81 17 7.99 7.88 11.79 3.98
L. R et al. / The Breast 52 (2020) 122e131 131ORs less than 1 imply a better QoL for the treatment including
goserelin: i.e. the odds of experiencing the symptomwere lower in
the group treated with goserelin.
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